Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation

Pirfenidone is a pleiotropic molecule approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone has demonstrated to downregulate transforming growth factor-β1 (TGF-β1) cellular effects. However, its anti-fibrotic mechanism remains unclear. Here, we aim to analyze the effects of pirfenidone...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballester, Beatriz, Milara, Javier, Cortijo, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170494/
https://www.ncbi.nlm.nih.gov/pubmed/32341751
http://dx.doi.org/10.18632/oncotarget.27526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170494/
https://www.ncbi.nlm.nih.gov/pubmed/32341751
http://dx.doi.org/10.18632/oncotarget.27526

Ejemplares similares